Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.1069
Abstract: 1069 Background: Endocrine therapy (ET) + CDK4/6i is the mainstay in 1st-line ER+/HER2- mBC; however, resistance to ET arises. De novo resistance mechanisms include alterations in the PI3K/AKT/mTOR or cell cycle pathways; acquired resistance mechanisms… read more here.
Keywords: resistance mechanisms; pts enrolled; her2; gr3 ... See more keywords
BAT8008, a TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1 study.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.3024
Abstract: 3024 Background: BAT8008 is a monoclonal ADC that delivers exatecan to cells expressing TROP-2. TROP-2 is a cell surface glycoprotein that can be expressed in certain normal tissue but is frequently overexpressed in multiple carcinomas… read more here.
Keywords: pts enrolled; adc; tumor; count decreased ... See more keywords